{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:26:43Z","timestamp":1792661203600,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/ico.0b013e31821379aa","type":"journal-article","created":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T15:46:59Z","timestamp":1308066419000},"page":"1110-1114","source":"Crossref","is-referenced-by-count":40,"title":["Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization"],"prefix":"10.1097","volume":"30","author":[{"given":"Sonia N","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Lichtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoz D","family":"Amiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan R","family":"Slomovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization. Pathogenesis and inhibition.","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"R2-7-20210204","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/archopht.123.10.1435","article-title":"Unusual idiopathic lipid keratopathy: a newly recognized entity?","volume":"123","author":"Loeffler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R3-7-20210204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease.","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"R4-7-20210204","first-page":"91","article-title":"Factors affecting the outcome of corneal transplantation.","volume":"63","author":"Coster","year":"1981","journal-title":"Ann R Coll Surg Engl"},{"key":"R6-7-20210204","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"R7-7-20210204","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-7-20210204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization.","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"R9-7-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1126\/science.2416056","article-title":"A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment.","volume":"230","author":"Crum","year":"1985","journal-title":"Science"},{"key":"R10-7-20210204","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R11-7-20210204","doi-asserted-by":"crossref","first-page":"363e5","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R12-7-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":"Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R13-7-20210204","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2009.173732","article-title":"Results of bevacizumab as the primary treatment for retinal vein occlusions.","volume":"94","author":"Figueroa","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R14-7-20210204","doi-asserted-by":"crossref","first-page":"1695:e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R15-7-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3129\/i09-259","article-title":"Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.","volume":"45","author":"Yeung","year":"2010","journal-title":"Can J Ophthalmol"},{"key":"R16-7-20210204","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/112067210901900414","article-title":"Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.","volume":"19","author":"Hasanreisoglu","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R17-7-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R18-7-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R19-7-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R20-7-20210204","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"R21-7-20210204","first-page":"1588","article-title":"Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat.","volume":"30","author":"Haynes","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-7-20210204","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","article-title":"Topical application of methotrexate for inhibition of corneal angiogenesis.","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-7-20210204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine.","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R24-7-20210204","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-7-20210204","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":"Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"R26-7-20210204","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"R27-7-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R28-7-20210204","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R29-7-20210204","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-7-20210204","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-7-20210204","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bjo.2008.145128","article-title":"Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.","volume":"93","author":"Bachmann","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R32-7-20210204","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R33-7-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R34-7-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R35-7-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R36-7-20210204","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation.","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R37-7-20210204","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/ICO.0b013e3181d92834","article-title":"Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.","volume":"29","author":"Foroutan","year":"2010","journal-title":"Cornea"},{"key":"R38-7-20210204","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"R39-7-20210204","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":"Early but not late treatment with bevacizumab (Avastin) can inhibit corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201110000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:30:28Z","timestamp":1786044628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201110000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31821379aa","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}